Related Experiment Videos
Cancer chemotherapy--ribonucleases to the rescue
1Department of Biochemistry, University of Wisconsin-Madison, 53706, USA.
Chemistry & Biology
|May 19, 2001
Abstract:
Ribonucleases, once dismissed as uninteresting digestive enzymes, have been shown to have remarkable biological activities. Onconase, from the Northern leopard frog, is currently in clinical trials as a cancer chemotherapeutic. Recent research has revealed some key factors responsible for the cytotoxicity of ribonucleases, and may lead to a new class of drugs.
Insights
Ribonucleases, enzymes once overlooked, exhibit significant biological functions. Research into Onconase, a frog-derived ribonuclease, highlights their potential as novel cancer chemotherapeutics.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Ribonucleases were historically considered simple digestive enzymes.
- Emerging research reveals diverse and significant biological activities of ribonucleases.
- Onconase, a ribonuclease from the Northern leopard frog, is under investigation for cancer treatment.
Purpose of the Study:
- To explore the cytotoxic mechanisms of ribonucleases.
- To identify key factors contributing to ribonuclease-induced cell death.
- To evaluate the therapeutic potential of ribonucleases in cancer therapy.
Main Methods:
- Investigating the biological activities of specific ribonucleases.
- Analyzing the molecular mechanisms underlying ribonuclease cytotoxicity.
- Clinical evaluation of Onconase as a chemotherapeutic agent.
Main Results:
- Ribonucleases possess potent cytotoxic effects.
- Key molecular factors driving ribonuclease cytotoxicity have been identified.
- Onconase demonstrates promise in ongoing clinical trials for cancer treatment.
Conclusions:
- Ribonucleases have critical biological roles beyond digestion.
- Understanding ribonuclease cytotoxicity can pave the way for new cancer drugs.
- Onconase represents a potential new class of chemotherapeutic agents.